VFA
FPRX

Virtus Fund Advisers’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Virtus Fund Advisers’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$381K Buy
+17,371
New +$559K ﹤0.01% 372
2014
Q3 		– Sell
-1,471
Closed -$23K – 2190
2014
Q2 		$23K Buy
+1,471
New +$21.1K ﹤0.01% 2365

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Virtus Fund Advisers's FPRX Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Five Prime Therapeutics, Inc. (FPRX) in Q4 2017: 17,371 shares worth $381K. The stake represents ﹤0.01% of the portfolio and ranks #372 among its holdings. This is a return to the name: Virtus Fund Advisers previously reported a position in FPRX as recently as Q2 2014.

Virtus Fund Advisers first reported a position in FPRX in Q2 2014 and has held it in 2 quarters since. 137 funds tracked by Wall St. Rank hold FPRX as of Q4 2017.

  • Virtus Fund Advisers held 17,371 shares of Five Prime Therapeutics, Inc. worth $381K as of Q4 2017.
  • Five Prime Therapeutics, Inc. was a new Virtus Fund Advisers position in Q4 2017.
  • Five Prime Therapeutics, Inc. made up ﹤0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #372 holding.
  • Virtus Fund Advisers first reported a position in Five Prime Therapeutics, Inc. in Q2 2014 and has held it in 2 quarters since.
  • 137 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.